<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03752437</url>
  </required_header>
  <id_info>
    <org_study_id>MDKR</org_study_id>
    <nct_id>NCT03752437</nct_id>
  </id_info>
  <brief_title>Comparison of Two Dosages of Heparin Before Extracorporeal Circulation</brief_title>
  <official_title>Comparison of Two Dosages of Heparin Before Extracorporeal Circulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators will study two dosages of heparin before extracorporeal
      circulation in open chest cardiac surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study the investigators will study two dosages of heparin before extracorporeal
      circulation in open chest cardiac surgery. The first dosage will be 300 IU per kilogram of
      REAL weight, the second dosage will be 300 IU per kilogram of IDEAL weight.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>One arm will receive 300 IU of heparin based on real weight, and the other arm will receive 300 IU of heparin based on ideal weight.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Randomisation by computer, different sheet for encoding data.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>ACT performance</measure>
    <time_frame>1 minute</time_frame>
    <description>Measure of ACT to be &gt; 400 seconds to allow extracorporeal circulation, but also &lt; 700 seconds to avoid excessive bleeding.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Extracorporeal Circulation; Complications</condition>
  <arm_group>
    <arm_group_label>Real Weight</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of 300 IU of heparin based on REAL weight. This injection will be controlled by an ACT (activated clotting time) one minute after the injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ideal Weight</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of 300 IU of heparin based on IDEAL weight. This injection will be controlled by an ACT (activated clotting time) one minute after the injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ACT (Activated Clotting Time)</intervention_name>
    <description>Measure of ACT in the two arms in order to determine if injection of heparin based on ideal weight is better or not than those one on real weight.</description>
    <arm_group_label>Ideal Weight</arm_group_label>
    <arm_group_label>Real Weight</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>300 IU of heparin</description>
    <arm_group_label>Ideal Weight</arm_group_label>
    <arm_group_label>Real Weight</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients admitted for cardiac open chest surgery

        Exclusion Criteria:

          -  Patient's refusal

          -  Antithrombin III factor &lt; 75%

          -  Patient under treatment by heparin IV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Deflandre, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Astes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Deflandre, MD, PhD</last_name>
    <phone>0032477764241</phone>
    <email>eric.deflandre@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique Saint-Luc of Bouge</name>
      <address>
        <city>Namur</city>
        <zip>5004</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric DEFLANDRE</last_name>
      <email>eric.deflandre@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 21, 2018</study_first_submitted>
  <study_first_submitted_qc>November 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2018</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Astes</investigator_affiliation>
    <investigator_full_name>Eric DEFLANDRE, MD, PhD, FCCP, FAHA</investigator_full_name>
    <investigator_title>Head of Department</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

